PARTNER NEWS:Fri, May 10, 11:34 AM, Zacks
bluebird (BLUE) Tops on Q1 Sales, Zynteglo Progresses Well
bluebird (BLUE) beats sales estimates in the first quarter on increased Zynteglo product revenues. The company is on track with the ongoing launch of its gene therapies.
Thu, May 9, 10:40 AM, Zacks
Editas (EDIT) Q1 Earnings & Revenues Lag Estimates, Stock Down
Editas (EDIT) reports weaker-than-expected first-quarter 2024 results as both earnings and revenues fall shy of estimates. Shares fall.